Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation

[1]  G. Patti,et al.  Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study‐level meta‐analysis of phase III randomized trials , 2017, Diabetes/metabolism research and reviews.

[2]  R. de Caterina,et al.  Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. , 2017, Circulation.

[3]  P. Noseworthy,et al.  Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Other Than Significant Mitral Stenosis and Mechanical Valves: A Meta-Analysis. , 2017, Circulation.

[4]  Ulrich Schotten,et al.  2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. , 2017, Revista espanola de cardiologia.

[5]  S. Khazaei,et al.  Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation: Methodological issues of prediction models. , 2016, International journal of cardiology.

[6]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[7]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[8]  L. Fauchier,et al.  Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study. , 2016, International journal of cardiology.

[9]  P. Sandset,et al.  Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH , 2016, Journal of thrombosis and haemostasis : JTH.

[10]  L. Fauchier,et al.  Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis , 2016, Thrombosis and Haemostasis.

[11]  L. Fauchier,et al.  CHA2DS2-VASc Score for Predicting Stroke and Thromboembolism in Patients With AF and Biological Valve Prosthesis. , 2016, Journal of the American College of Cardiology.

[12]  D. Atar,et al.  Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. , 2015, European heart journal.

[13]  G. Lip,et al.  Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. , 2015, European heart journal.

[14]  L. Fauchier,et al.  How to define valvular atrial fibrillation? , 2015, Archives of cardiovascular diseases.

[15]  A. Camm,et al.  Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[16]  G. Breithardt,et al.  Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial , 2014, European heart journal.

[17]  A. Banerjee,et al.  A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. , 2014, Chest.

[18]  R. de Caterina,et al.  Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. , 2014, Journal of the American College of Cardiology.

[19]  C. Kearon,et al.  Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta‐analysis , 2014, Journal of thrombosis and haemostasis : JTH.

[20]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[21]  G. Breithardt,et al.  Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). , 2014, Journal of the American College of Cardiology.

[22]  Z. Harel,et al.  Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. , 2014, Journal of the American Society of Nephrology : JASN.

[23]  F. Marchlinski,et al.  Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. , 2014, The American journal of cardiology.

[24]  W. Abhayaratna,et al.  Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. , 2013, JAMA.

[25]  J. Le Heuzey,et al.  Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. , 2013, Archives of cardiovascular diseases.

[26]  A. Camm,et al.  "R" for "renal" and for "risk": refining risk stratification for stroke in atrial fibrillation. , 2013, Circulation.

[27]  Gregory Y H Lip,et al.  New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation , 2012, Expert review of cardiovascular therapy.

[28]  S. Yusuf,et al.  Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. , 2015, International journal of cardiology.

[29]  M. Keltai,et al.  Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. , 2012, European heart journal.

[30]  L. Køber,et al.  Stroke and bleeding in atrial fibrillation with chronic kidney disease. , 2012, The New England journal of medicine.

[31]  S. Connolly,et al.  A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). , 2012, American heart journal.

[32]  C. Richards,et al.  Emergency hospitalizations for adverse drug events in older Americans. , 2011, The New England journal of medicine.

[33]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[34]  Jun Zhu,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[35]  G. Lip,et al.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.

[36]  P. Vestergaard,et al.  Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. , 2005, The American journal of medicine.

[37]  L. Fried,et al.  Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[38]  D. Singer,et al.  Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 1999, Annals of Internal Medicine.

[39]  G. Lip,et al.  Is There an Obesity Paradox for Outcomes in Atrial Fibrillation?: A Systematic Review and Meta-Analysis of Non–Vitamin K Antagonist Oral Anticoagulant Trials , 2017, Stroke.

[40]  P. Noseworthy,et al.  Meta-Analysis of Renal Function on the Safety and Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation. , 2016, The American journal of cardiology.

[41]  D. Parish,et al.  Obesity and the risk of new-onset atrial fibrillation. , 2005, JAMA.